T1	Condition 64 103	Myasthenia Gravis Foundation of America
T2	Condition-Name 64 103	Myasthenia Gravis Foundation of America
E1	Condition:T1 Name:T2
T3	Life-Stage-And-Gender 33 39	female
A1	Life-Stage-And-Gender-Type T3 female
T4	Life-Stage-And-Gender 25 29	Male
A2	Life-Stage-And-Gender-Type T4 male
T7	Procedure 435 451	immunomodulation
T8	Procedure-Name 435 451	immunomodulation
E7	Procedure:T7 Name:T8 Temporality:E17
T9	Procedure 578 593	plasma exchange
T10	Procedure-Name 578 593	plasma exchange
E9	Procedure:T9 Name:T10
T11	Procedure 563 577	plasmapheresis
T12	Procedure-Name 563 577	plasmapheresis
E11	Procedure:T11 Name:T12
T13	Procedure 637 647	Thymectomy
T14	Procedure-Name 637 647	Thymectomy
E13	Procedure:T13 Name:T14 Temporality:E19
T15	Eq-Operator 40 41	≥
A3	Eq-Operator-Value T15 GTEQ
T16	Eq-Operator 239 240	≥
A4	Eq-Operator-Value T16 GTEQ
T17	Eq-Operator 452 458	within
A5	Eq-Operator-Value T17 LTEQ
T18	Eq-Operator 599 605	within
A6	Eq-Operator-Value T18 LTEQ
T19	Eq-Operator 658 659	<
A7	Eq-Operator-Value T19 LT
T20	Eq-Operator 711 712	<
A8	Eq-Operator-Value T20 LT
T21	Eq-Operator 765 766	<
A9	Eq-Operator-Value T21 LT
T22	Eq-Temporal-Unit 45 50	years
A10	Eq-Temporal-Unit-Value T22 year
T23	Eq-Temporal-Unit 461 467	months
A11	Eq-Temporal-Unit-Value T23 month
T24	Eq-Temporal-Unit 608 613	weeks
A12	Eq-Temporal-Unit-Value T24 week
T25	Eq-Temporal-Unit 663 669	months
A13	Eq-Temporal-Unit-Value T25 month
T26	Eq-Unit 777 780	mm3
T27	Age 54 57	age
E14	Age:T27 Eq-Comparison:E15
T28	Eq-Value 42 44	18
T29	Eq-Value 240 242	12
T30	Eq-Value 459 460	6
T31	Eq-Value 606 607	4
T32	Eq-Value 660 662	12
T33	Eq-Value 712 713	6
T34	Eq-Value 766 770	1500
T35	Eq-Comparison 40 50	≥ 18 years
E15	Eq-Comparison:T35 Operator:T15 Temporal-Unit:T22 Value:T28
T36	Eq-Comparison 239 242	≥12
E16	Eq-Comparison:T36 Operator:T16 Value:T29
T37	Eq-Comparison 452 467	within 6 months
E17	Eq-Comparison:T37 Operator:T17 Temporal-Unit:T23 Value:T30
T38	Eq-Comparison 599 613	within 4 weeks
E18	Eq-Comparison:T38 Operator:T18 Temporal-Unit:T24 Value:T31
T39	Eq-Comparison 658 669	< 12 months
E19	Eq-Comparison:T39 Operator:T19 Temporal-Unit:T25 Value:T32
T40	Eq-Comparison 711 717	<6 g/L
E20	Eq-Comparison:T40 Operator:T20 Value:T33 Unit:T82 Per:T83
T41	Eq-Comparison 765 780	<1500 cells/mm3
E21	Eq-Comparison:T41 Operator:T21 Value:T34 Unit:T86 Per:T26
T5	Procedure 152 162	respirator
E2	Procedure:T5 Name:T6
T6	Procedure-Name 152 162	respirator
T42	Negation 135 138	not
E3	Negation:T42 Negates:E2
T43	Study 187 192	study
E4	Study:T43 
T44	Temporal-Connection 163 179	for the duration
E5	Temporal-Connection:T44 Arg:E2 Arg2:E4
A14	Temporal-Connection-Type-Value E5 during
T46	Observation 229 232	QMG
E8	Observation:T46 Name:T47 Eq-Comparison:E16
T47	Observation-Name 229 232	QMG
A16	Observation-Type-Value T47 clinical-score
T48	Drug 371 380	rituximab
E10	Drug:T48 Name:T49
T49	Drug-Name 371 380	rituximab
T50	Drug 382 391	belimumab
E12	Drug:T50 Name:T51
T51	Drug-Name 382 391	belimumab
T52	Drug 393 403	eculizumab
E22	Drug:T52 Name:T53
T53	Drug-Name 393 403	eculizumab
T54	Drug 411 430	monoclonal antibody
E23	Drug:T54 Name:T55
T55	Drug-Name 411 430	monoclonal antibody
T56	Or 404 406	or
E24	Or:T56 Arg:E22 Arg2:E23
R1	Using Arg1:E7 Arg2:E23	
R2	Using Arg1:E7 Arg2:E22	
R3	Using Arg1:E7 Arg2:E12	
R4	Using Arg1:E7 Arg2:E10	
T57	Procedure 483 489	dosing
E25	Procedure:T57 Name:T58 Temporality:E26
T58	Procedure-Name 483 489	dosing
T59	Eq-Temporal-Recency 477 482	first
A17	Eq-Temporal-Recency-Value T59 first-time
T60	Eq-Comparison 477 482	first
E26	Eq-Comparison:T60 Temporal-Recency:T59
T61	Temporal-Connection 468 473	prior
E27	Temporal-Connection:T61 Arg2:E25 Arg:E17
A18	Temporal-Connection-Type-Value E27 before
T62	Drug 496 511	Immunoglobulins
E28	Drug:T62 Name:T63 Temporality:E18
T63	Drug-Name 496 511	Immunoglobulins
T72	Or 536 538	or
E33	Or:T72 Arg:E31 Arg2:E32
T73	Or 560 562	or
E34	Or:T73 Arg:E28 Arg2:E11
T74	Procedure 595 597	PE
E35	Procedure:T74 Name:T75
T75	Procedure-Name 595 597	PE
R6	Abbrev-Of Arg1:E35 Arg2:E9	
T76	Temporal-Connection 614 620	before
E36	Temporal-Connection:T76 Arg:E18 Arg2:E37
A19	Temporal-Connection-Type-Value E36 before
T77	Study 621 630	Screening
E37	Study:T77 
T78	Temporal-Connection 670 678	prior to
E38	Temporal-Connection:T78 Arg:E19 Arg2:E39
A20	Temporal-Connection-Type-Value E38 before
T79	Study 679 688	screening
E39	Study:T79 
T80	Observation 695 704	Total IgG
E40	Observation:T80 Name:T81 Eq-Comparison:E20
T81	Observation-Name 695 704	Total IgG
A21	Observation-Type-Value T81 clinical-score
T82	Eq-Unit 714 715	g
T83	Eq-Unit 716 717	L
T84	Observation 739 764	Absolute neutrophil count
E41	Observation:T84 Name:T85 Eq-Comparison:E21
T85	Observation-Name 739 764	Absolute neutrophil count
T86	Eq-Unit 771 776	cells
T87	Or 30 32	or
E42	Or:T87 Arg:T4 Arg2:T3
T88	Condition 105 109	MGFA
E43	Condition:T88 Name:T89 Stage:E44
T89	Condition-Name 105 109	MGFA
R7	Abbrev-Of Arg1:E43 Arg2:E1	
T90	Eq-Comparison 111 123	Class II-IVa
E44	Eq-Comparison:T90 Operator:T93 Unit:T94 Value:T91 Value2:T92
T91	Eq-Value 117 119	II
T92	Eq-Value 120 123	IVa
T93	Eq-Operator 119 120	-
A22	Eq-Operator-Value T93 BETWEEN
T94	Eq-Unit 111 116	Class
T95	Assertion 128 134	likely
E45	Assertion:T95 Asserted:E3
A23	Assertion-Type-Value E45 hypothetical
T96	And 124 127	and
E46	And:T96 Arg:E43 Arg2:E45
T97	Assertion 142 149	need of
E47	Assertion:T97 Asserted:E2
A24	Assertion-Type-Value E47 hypothetical
T45	Study 246 255	Screening
E6	Study:T45 
T98	Study 260 268	Baseline
E48	Study:T98 
T99	And 256 259	and
E49	And:T99 Arg:E6 Arg2:E48
T100	Temporal-Connection 243 245	at
E50	Temporal-Connection:T100 Arg:E8 Arg2:E6
A15	Temporal-Connection-Type-Value E50 during
T101	Study 784 793	screening
E51	Study:T101 
T102	Temporal-Connection 781 783	at
E52	Temporal-Connection:T102 Arg:E41 Arg2:E51
A25	Temporal-Connection-Type-Value E52 during
T103	Study 722 731	screening
E53	Study:T103 
T104	Temporal-Connection 719 721	at
E54	Temporal-Connection:T104 Arg:E40 Arg2:E53
A26	Temporal-Connection-Type-Value E54 during
T64	Modifier 521 523	SC
E29	Modifier:T64 Modifies:T63
T65	Modifier 525 527	IV
E30	Modifier:T65 Modifies:T63
T66	Modifier 529 533	IVIG
E31	Modifier:T66 
R5	Abbrev-Of Arg1:E31 Arg2:E30	
T67	Modifier 539 558	intramuscular route
E32	Modifier:T67 Modifies:T63
R8	Using Arg1:E28 Arg2:E11	
R9	Using Arg1:E28 Arg2:E9	
